AbbVie Inc. $ABBV Shares Acquired by Mather Group LLC.

Posted by Francis Steltz on Oct 15th, 2026

Mather Group LLC. increased its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 5.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 35,883 shares of the company’s stock after buying an additional 1,893 shares during the quarter. Mather Group LLC.’s holdings in AbbVie were worth $9,387,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. State Street Corp increased its holdings in shares of AbbVie by 1.7% during the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock valued at $20,784,646,000 after acquiring an additional 1,379,232 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of AbbVie by 0.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock worth $3,590,323,000 after purchasing an additional 106,091 shares during the period. Legal & General Group Plc acquired a new position in shares of AbbVie during the second quarter worth approximately $2,905,952,000. Deutsche Bank AG raised its position in shares of AbbVie by 13.0% during the second quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock worth $2,710,905,000 after purchasing an additional 1,241,587 shares during the period. Finally, Amundi lifted its holdings in shares of AbbVie by 2.4% in the 1st quarter. Amundi now owns 10,698,095 shares of the company’s stock worth $2,326,728,000 after purchasing an additional 247,689 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

Insider Transactions at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.06% of the company’s stock.

AbbVie Stock Performance

ABBV stock opened at $283.58 on Thursday. The business has a 50-day simple moving average of $261.16 and a two-hundred day simple moving average of $238.38. The company has a market capitalization of $501.03 billion, a P/E ratio of 80.11, a price-to-earnings-growth ratio of 1.25 and a beta of 0.24. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $285.40.

AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the business posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts forecast that AbbVie Inc. will post 13.95 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Thursday, October 15th. This represents a $6.92 annualized dividend and a yield of 2.4%. AbbVie’s dividend payout ratio is 195.48%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: Positive SKYRIZI Crohn’s disease data: Phase 3 AFFIRM results showed that subcutaneous SKYRIZI produced meaningful clinical and endoscopic benefits versus placebo, with a safety profile consistent with the established treatment. The data could support regulatory review of a more convenient induction option and strengthen AbbVie’s post-Humira growth franchise. Did SKYRIZI’s Subcutaneous Crohn’s Data Just Shift AbbVie’s Investment Narrative?
Positive Sentiment: Analyst and earnings optimism: RBC reaffirmed an “outperform” rating and cited potential third-quarter strength from RINVOQ, SKYRIZI, and Vraylar. Erste Group also raised its FY2027 EPS estimate to $16.34 from $16.19 while maintaining a “Buy” rating. Investors are looking ahead to AbbVie’s October 30 earnings report. AbbVie Poised for Q3 Top-Line Beat
Positive Sentiment: Broad healthcare rally and options activity: Pharmaceutical stocks rallied broadly, supporting ABBV. Investors also purchased 86,296 AbbVie call options, approximately 445% above typical call volume, indicating elevated bullish positioning, although options activity alone does not guarantee further gains. Lilly, Merck, AbbVie Stocks Surge
Neutral Sentiment: Mixed comparative view: A Zacks analysis argued that Sanofi currently offers a more attractive combination of valuation, outlook, and Dupixent growth, suggesting AbbVie’s strong recent performance has left less valuation upside relative to some peers. Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?
Negative Sentiment: Valuation and conflicting market reaction: One report characterized ABBV as trading above estimated fair value, while another described an initial decline following the new SKYRIZI data. The conflicting reactions highlight execution, regulatory, and valuation risks despite the data’s long-term potential. A Look at AbbVie After a Decline

Analyst Ratings Changes

Several analysts recently issued reports on the stock. BMO Capital Markets lifted their price target on shares of AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Argus boosted their price target on shares of AbbVie from $250.00 to $270.00 in a research note on Tuesday, August 4th. Barclays upped their price objective on shares of AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Guggenheim reaffirmed a “buy” rating and issued a $288.00 price objective on shares of AbbVie in a research note on Friday, October 9th. Finally, Wolfe Research raised shares of AbbVie from a “peer perform” rating to an “outperform” rating and raised their price objective for the company from $235.00 to $300.00 in a research note on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and an average price target of $277.18.

Check Out Our Latest Stock Analysis on AbbVie

AbbVie Profile

(Free Report)

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.